25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ADMA Biologics Inc
Buy, Hold or Sell?

Let's analyze ADMA Biologics Inc together

I guess you are interested in ADMA Biologics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of ADMA Biologics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about ADMA Biologics Inc

I send you an email if I find something interesting about ADMA Biologics Inc.

1. Quick Overview

1.1. Quick analysis of ADMA Biologics Inc (30 sec.)










1.2. What can you expect buying and holding a share of ADMA Biologics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$0.95
Expected worth in 1 year
$1.25
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$0.31
Return On Investment
1.6%

For what price can you sell your share?

Current Price per Share
$19.01
Expected price per share
$15.33 - $23.64
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of ADMA Biologics Inc (5 min.)




Live pricePrice per Share (EOD)
$19.01
Intrinsic Value Per Share
$0.12 - $8.86
Total Value Per Share
$1.06 - $9.81

2.2. Growth of ADMA Biologics Inc (5 min.)




Is ADMA Biologics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$231.8m$148.9m$28.3m16.0%

How much money is ADMA Biologics Inc making?

Current yearPrevious yearGrowGrow %
Making money$17m-$10.6m$27.6m162.4%
Net Profit Margin14.4%-20.3%--

How much money comes from the company's main activities?

2.3. Financial Health of ADMA Biologics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#229 / 945

Most Revenue
#77 / 945

Most Profit
#57 / 945
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of ADMA Biologics Inc?

Welcome investor! ADMA Biologics Inc's management wants to use your money to grow the business. In return you get a share of ADMA Biologics Inc.

First you should know what it really means to hold a share of ADMA Biologics Inc. And how you can make/lose money.

Speculation

The Price per Share of ADMA Biologics Inc is $19.01. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of ADMA Biologics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in ADMA Biologics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.95. Based on the TTM, the Book Value Change Per Share is $0.08 per quarter. Based on the YOY, the Book Value Change Per Share is $0.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of ADMA Biologics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.150.8%0.070.4%-0.02-0.1%-0.04-0.2%-0.04-0.2%
Usd Book Value Change Per Share0.170.9%0.080.4%0.050.3%0.040.2%0.020.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.170.9%0.080.4%0.060.3%0.040.2%0.020.1%
Usd Price Per Share19.99-10.57-3.62-4.15-5.02-
Price to Earnings Ratio34.07-15.49-0.17--1.67--31.05-
Price-to-Total Gains Ratio117.72-56.03-179.60-10.87--80.31-
Price to Book Ratio21.10-13.38-5.73-8.35--193.04-
Price-to-Total Gains Ratio117.72-56.03-179.60-10.87--80.31-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share19.01
Number of shares52
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.080.04
Usd Total Gains Per Share0.080.04
Gains per Quarter (52 shares)3.992.09
Gains per Year (52 shares)15.948.36
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1016608-2
2032220176
30483802514
40645403322
50807014130
60968615038
7011210215846
8012811816654
9014313417462
10015915018370

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%4.08.00.033.3%4.016.00.020.0%4.036.00.010.0%4.068.00.05.6%
Book Value Change Per Share3.01.00.075.0%7.05.00.058.3%10.010.00.050.0%16.024.00.040.0%21.037.014.029.2%
Dividend per Share0.00.04.00.0%2.00.010.016.7%2.00.018.010.0%2.00.038.05.0%2.00.070.02.8%
Total Gains per Share3.01.00.075.0%7.05.00.058.3%10.010.00.050.0%16.024.00.040.0%21.037.014.029.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of ADMA Biologics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1700.077+122%0.054+215%0.040+327%0.023+648%
Book Value Per Share--0.9470.737+29%0.630+50%0.521+82%0.295+221%
Current Ratio--7.0886.082+17%6.741+5%7.361-4%6.399+11%
Debt To Asset Ratio--0.4060.514-21%0.569-29%0.572-29%0.707-43%
Debt To Equity Ratio--0.6841.100-38%1.319-48%1.435-52%2.628-74%
Dividend Per Share----0%0.002-100%0.000-100%0.000-100%
Enterprise Value--4821612259.3502440875948.178+98%731287551.250+559%896125643.636+438%1133710500.268+325%
Eps--0.1470.070+110%-0.024+116%-0.036+124%-0.038+126%
Ev To Ebitda Ratio--28.5728.523+235%-64.097+324%-16.891+159%-43.165+251%
Ev To Sales Ratio--10.0595.893+71%3.170+217%6.648+51%75.953-87%
Free Cash Flow Per Share--0.0990.082+21%-0.025+125%-0.057+158%-0.050+150%
Free Cash Flow To Equity Per Share---0.0050.013-138%0.042-112%0.008-160%0.006-186%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--8.858--------
Intrinsic Value_10Y_min--0.115--------
Intrinsic Value_1Y_max--0.074--------
Intrinsic Value_1Y_min---0.165--------
Intrinsic Value_3Y_max--0.841--------
Intrinsic Value_3Y_min---0.345--------
Intrinsic Value_5Y_max--2.357--------
Intrinsic Value_5Y_min---0.360--------
Market Cap4493773900.000-9%4893633259.3502557469698.178+91%854549850.000+473%993138564.636+393%1192442344.818+310%
Net Profit Margin--0.3000.144+108%-0.203+168%-0.728+343%-1.688+663%
Operating Margin--0.3360.204+64%-0.001+100%-0.514+253%-1.455+533%
Operating Ratio--0.6690.711-6%1.004-33%1.498-55%2.447-73%
Pb Ratio20.069-5%21.10313.384+58%5.735+268%8.353+153%-193.039+1015%
Pe Ratio32.399-5%34.07015.487+120%0.173+19622%-1.668+105%-31.053+191%
Price Per Share19.010-5%19.99010.573+89%3.615+453%4.152+381%5.020+298%
Price To Free Cash Flow Ratio47.905-5%50.375-0.664+101%-11.240+122%-5.580+111%-35.455+170%
Price To Total Gains Ratio111.947-5%117.71856.033+110%179.601-34%10.874+983%-80.305+168%
Quick Ratio--3.0482.274+34%2.523+21%3.070-1%4.047-25%
Return On Assets--0.0920.044+111%-0.031+133%-0.047+152%-0.108+217%
Return On Equity--0.1550.078+99%-0.071+146%-0.128+183%-0.454+393%
Total Gains Per Share--0.1700.077+122%0.056+201%0.040+322%0.023+640%
Usd Book Value--231890000.000177267750.000+31%148957119.000+56%123685081.100+87%69985144.925+231%
Usd Book Value Change Per Share--0.1700.077+122%0.054+215%0.040+327%0.023+648%
Usd Book Value Per Share--0.9470.737+29%0.630+50%0.521+82%0.295+221%
Usd Dividend Per Share----0%0.002-100%0.000-100%0.000-100%
Usd Enterprise Value--4821612259.3502440875948.178+98%731287551.250+559%896125643.636+438%1133710500.268+325%
Usd Eps--0.1470.070+110%-0.024+116%-0.036+124%-0.038+126%
Usd Free Cash Flow--24286000.00019793934.500+23%-5874393.500+124%-13423481.900+155%-11729915.325+148%
Usd Free Cash Flow Per Share--0.0990.082+21%-0.025+125%-0.057+158%-0.050+150%
Usd Free Cash Flow To Equity Per Share---0.0050.013-138%0.042-112%0.008-160%0.006-186%
Usd Market Cap4493773900.000-9%4893633259.3502557469698.178+91%854549850.000+473%993138564.636+393%1192442344.818+310%
Usd Price Per Share19.010-5%19.99010.573+89%3.615+453%4.152+381%5.020+298%
Usd Profit--35909000.00017033116.750+111%-10625163.500+130%-10318169.000+129%-9865813.100+127%
Usd Revenue--119839000.00095702169.250+25%58573194.500+105%42819957.450+180%23319611.000+414%
Usd Total Gains Per Share--0.1700.077+122%0.056+201%0.040+322%0.023+640%
 EOD+4 -4MRQTTM+31 -6YOY+30 -95Y+29 -1010Y+29 -10

3.3 Fundamental Score

Let's check the fundamental score of ADMA Biologics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1532.399
Price to Book Ratio (EOD)Between0-120.069
Net Profit Margin (MRQ)Greater than00.300
Operating Margin (MRQ)Greater than00.336
Quick Ratio (MRQ)Greater than13.048
Current Ratio (MRQ)Greater than17.088
Debt to Asset Ratio (MRQ)Less than10.406
Debt to Equity Ratio (MRQ)Less than10.684
Return on Equity (MRQ)Greater than0.150.155
Return on Assets (MRQ)Greater than0.050.092
Total8/10 (80.0%)

3.4 Technical Score

Let's check the technical score of ADMA Biologics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.357
Ma 20Greater thanMa 5020.596
Ma 50Greater thanMa 10019.044
Ma 100Greater thanMa 20017.677
OpenGreater thanClose19.960
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Fundamental data was last updated by Penke on 2024-12-05 11:28:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit ADMA Biologics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 30.0% means that $0.30 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of ADMA Biologics Inc:

  • The MRQ is 30.0%. The company is making a huge profit. +2
  • The TTM is 14.4%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ30.0%TTM14.4%+15.5%
TTM14.4%YOY-20.3%+34.7%
TTM14.4%5Y-72.8%+87.3%
5Y-72.8%10Y-168.8%+96.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ30.0%-109.4%+139.4%
TTM14.4%-221.4%+235.8%
YOY-20.3%-208.7%+188.4%
5Y-72.8%-346.2%+273.4%
10Y-168.8%-470.4%+301.6%
4.3.1.2. Return on Assets

Shows how efficient ADMA Biologics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
  • 9.2% Return on Assets means that ADMA Biologics Inc generated $0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of ADMA Biologics Inc:

  • The MRQ is 9.2%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 4.4%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ9.2%TTM4.4%+4.8%
TTM4.4%YOY-3.1%+7.4%
TTM4.4%5Y-4.7%+9.1%
5Y-4.7%10Y-10.8%+6.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.2%-11.6%+20.8%
TTM4.4%-12.0%+16.4%
YOY-3.1%-11.2%+8.1%
5Y-4.7%-12.6%+7.9%
10Y-10.8%-14.2%+3.4%
4.3.1.3. Return on Equity

Shows how efficient ADMA Biologics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
  • 15.5% Return on Equity means ADMA Biologics Inc generated $0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of ADMA Biologics Inc:

  • The MRQ is 15.5%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 7.8%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ15.5%TTM7.8%+7.7%
TTM7.8%YOY-7.1%+14.9%
TTM7.8%5Y-12.8%+20.6%
5Y-12.8%10Y-45.4%+32.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.5%-14.5%+30.0%
TTM7.8%-16.0%+23.8%
YOY-7.1%-14.6%+7.5%
5Y-12.8%-18.6%+5.8%
10Y-45.4%-19.3%-26.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of ADMA Biologics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient ADMA Biologics Inc is operating .

  • Measures how much profit ADMA Biologics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
  • An Operating Margin of 33.6% means the company generated $0.34  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of ADMA Biologics Inc:

  • The MRQ is 33.6%. The company is operating very efficient. +2
  • The TTM is 20.4%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ33.6%TTM20.4%+13.1%
TTM20.4%YOY-0.1%+20.5%
TTM20.4%5Y-51.4%+71.8%
5Y-51.4%10Y-145.5%+94.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ33.6%-203.3%+236.9%
TTM20.4%-316.3%+336.7%
YOY-0.1%-216.5%+216.4%
5Y-51.4%-378.6%+327.2%
10Y-145.5%-480.3%+334.8%
4.3.2.2. Operating Ratio

Measures how efficient ADMA Biologics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.67 means that the operating costs are $0.67 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of ADMA Biologics Inc:

  • The MRQ is 0.669. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.711. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.669TTM0.711-0.042
TTM0.711YOY1.004-0.292
TTM0.7115Y1.498-0.786
5Y1.49810Y2.447-0.949
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6692.284-1.615
TTM0.7113.198-2.487
YOY1.0043.263-2.259
5Y1.4984.651-3.153
10Y2.4476.419-3.972
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of ADMA Biologics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if ADMA Biologics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.09 means the company has $7.09 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of ADMA Biologics Inc:

  • The MRQ is 7.088. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.082. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.088TTM6.082+1.006
TTM6.082YOY6.741-0.659
TTM6.0825Y7.361-1.279
5Y7.36110Y6.399+0.963
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0883.601+3.487
TTM6.0823.872+2.210
YOY6.7414.655+2.086
5Y7.3615.973+1.388
10Y6.3996.258+0.141
4.4.3.2. Quick Ratio

Measures if ADMA Biologics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 3.05 means the company can pay off $3.05 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of ADMA Biologics Inc:

  • The MRQ is 3.048. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.274. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.048TTM2.274+0.774
TTM2.274YOY2.523-0.248
TTM2.2745Y3.070-0.795
5Y3.07010Y4.047-0.977
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0483.093-0.045
TTM2.2743.416-1.142
YOY2.5234.393-1.870
5Y3.0705.954-2.884
10Y4.0476.436-2.389
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of ADMA Biologics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of ADMA Biologics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare ADMA Biologics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.41 means that ADMA Biologics Inc assets are financed with 40.6% credit (debt) and the remaining percentage (100% - 40.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of ADMA Biologics Inc:

  • The MRQ is 0.406. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.514. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.406TTM0.514-0.108
TTM0.514YOY0.569-0.054
TTM0.5145Y0.572-0.057
5Y0.57210Y0.707-0.135
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4060.345+0.061
TTM0.5140.346+0.168
YOY0.5690.311+0.258
5Y0.5720.365+0.207
10Y0.7070.382+0.325
4.5.4.2. Debt to Equity Ratio

Measures if ADMA Biologics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 68.4% means that company has $0.68 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of ADMA Biologics Inc:

  • The MRQ is 0.684. The company is very able to pay all its debts with equity. +2
  • The TTM is 1.100. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ0.684TTM1.100-0.416
TTM1.100YOY1.319-0.218
TTM1.1005Y1.435-0.334
5Y1.43510Y2.628-1.193
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6840.393+0.291
TTM1.1000.431+0.669
YOY1.3190.384+0.935
5Y1.4350.452+0.983
10Y2.6280.497+2.131
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings ADMA Biologics Inc generates.

  • Above 15 is considered overpriced but always compare ADMA Biologics Inc to the Biotechnology industry mean.
  • A PE ratio of 34.07 means the investor is paying $34.07 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of ADMA Biologics Inc:

  • The EOD is 32.399. Based on the earnings, the company is overpriced. -1
  • The MRQ is 34.070. Based on the earnings, the company is overpriced. -1
  • The TTM is 15.487. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD32.399MRQ34.070-1.670
MRQ34.070TTM15.487+18.582
TTM15.487YOY0.173+15.315
TTM15.4875Y-1.668+17.155
5Y-1.66810Y-31.053+29.385
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD32.399-2.259+34.658
MRQ34.070-2.480+36.550
TTM15.487-3.148+18.635
YOY0.173-3.244+3.417
5Y-1.668-5.991+4.323
10Y-31.053-6.692-24.361
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of ADMA Biologics Inc:

  • The EOD is 47.905. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 50.375. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is -0.664. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD47.905MRQ50.375-2.470
MRQ50.375TTM-0.664+51.039
TTM-0.664YOY-11.240+10.576
TTM-0.6645Y-5.580+4.916
5Y-5.58010Y-35.455+29.875
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD47.905-2.995+50.900
MRQ50.375-3.289+53.664
TTM-0.664-3.668+3.004
YOY-11.240-4.472-6.768
5Y-5.580-8.001+2.421
10Y-35.455-9.190-26.265
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of ADMA Biologics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 21.10 means the investor is paying $21.10 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of ADMA Biologics Inc:

  • The EOD is 20.069. Based on the equity, the company is expensive. -2
  • The MRQ is 21.103. Based on the equity, the company is expensive. -2
  • The TTM is 13.384. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD20.069MRQ21.103-1.035
MRQ21.103TTM13.384+7.719
TTM13.384YOY5.735+7.650
TTM13.3845Y8.353+5.031
5Y8.35310Y-193.039+201.392
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD20.0692.001+18.068
MRQ21.1032.054+19.049
TTM13.3842.385+10.999
YOY5.7352.431+3.304
5Y8.3533.690+4.663
10Y-193.0394.307-197.346
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of ADMA Biologics Inc.

4.8.1. Institutions holding ADMA Biologics Inc

Institutions are holding 90.888% of the shares of ADMA Biologics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30BlackRock Inc7.88730.0047186447114454342.4475
2024-09-30Vanguard Group Inc7.66470.006518118494360184224.8118
2024-09-30State Street Corp5.50150.010613004993494506361.3537
2024-09-30Amvescap Plc.5.33850.048712619769-550967-4.1833
2024-09-30Morgan Stanley - Brokerage Accounts3.63790.01258599618-597356-6.4951
2024-09-30Nuveen Asset Management, LLC2.78260.03696577877-2347261-26.2994
2024-09-30Geode Capital Management, LLC2.27670.008753819851379892.6314
2024-09-30D. E. Shaw & Co LP2.22690.09035264095-1560422-22.8649
2024-09-30Two Sigma Advisers, LLC1.88430.20864454400-200200-4.3011
2024-09-30Awm Investment Company Inc1.883610.78334452677-644948-12.6519
2024-09-30American Century Companies Inc1.78080.04894209653-1844664-30.4686
2024-09-30Dimensional Fund Advisors, Inc.1.70250.0195402465986669927.4449
2024-09-30Renaissance Technologies Corp1.55130.11023667196108506142.0219
2024-09-30Two Sigma Investments LLC1.51930.15733591375-436225-10.8309
2024-09-30Assenagon Asset Management SA1.46980.12783474455922812.7285
2024-09-30Lord, Abbett & Co LLC1.3090.2015309445730944570
2024-06-30Deutsche Bank AG1.28780.01543044175-8269-0.2709
2024-09-30Oberweis Asset Management Inc1.22982.9775290708086638042.455
2024-09-30Goldman Sachs Group Inc1.10480.008426116771578574152.7993
2024-09-30Northern Trust Corp1.02780.008242968835591917.1629
Total 55.066914.8853130173034+8879387+6.8%

4.9.2. Funds holding ADMA Biologics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-11-27iShares Core S&P Small-Cap ETF6.37890.34831507899767200.0446
2024-10-31Vanguard Total Stock Mkt Idx Inv3.01180.00677119521-33043-0.462
2024-11-27iShares Russell 2000 ETF2.64470.16926251874-13062-0.2085
2024-11-27SPDR® S&P Biotech ETF1.81241.26024284333-130050-2.9461
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr1.45870.05183448144-12636-0.3651
2024-10-31Xtrackers MSCI World Swap ETF 1C1.33150.7058314761900
2024-08-31CREF Stock R11.18460.03752800231-102609-3.5348
2024-10-31Invesco Main Street Small Cap R61.15352.226272682400
2024-09-30Invesco Small Cap Core1.15352.64042726824-882104-24.4423
2024-09-30American Century U.S. Small Cap Growth1.07041.21462530248-242707-8.7526
2024-09-30American Century Small Cap Growth Inv1.07041.21812530248-242707-8.7526
2024-09-30Lord Abbett Developing Growth A1.00331.8973237172400
2024-09-30Fidelity Small Cap Index0.97030.1672293781-12972-0.5623
2024-11-27iShares S&P Small-Cap 600 Growth ETF0.96550.7145228245700
2024-11-27SPDR® Portfolio S&P 600™ Sm Cap ETF0.89940.3484212616215680.0738
2024-06-30Oberweis Micro-Cap0.86334.46342040700-750000-26.875
2024-06-30Oberweis Micro-Cap Growth0.86334.45952040700-750000-26.875
2024-11-27iShares Russell 2000 Growth ETF0.86070.3322203466500
2024-10-31Vanguard Tax-Managed Small Cap Adm0.68780.28441625951-13176-0.8038
2024-09-30Nuveen Quant Small Cap Equity R60.68730.92411624660-67700-4.0003
Total 30.071323.469471085663-3244478-4.6%

5.3. Insider Transactions

Insiders are holding 2.51% of the shares of ADMA Biologics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-11-22Brad L TadeSELL1500021.15
2024-09-09Lawrence P GuiheenSELL900018.47
2024-08-30Kaitlin M Kestenberg-messinaSELL2415016.9
2024-08-29Jerrold B GrossmanSELL13686117.27
2024-08-26Adam S GrossmanSELL23688917.69
2024-08-23Young KwonSELL6000018.26
2024-06-14Adam S GrossmanSELL10000010.72
2024-03-18Steve ElmsSELL498876.01
2024-03-15Steve ElmsSELL1830086.01
2024-03-13Steve ElmsSELL4070006.21
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets390,618
Total Liabilities158,728
Total Stockholder Equity231,890
 As reported
Total Liabilities 158,728
Total Stockholder Equity+ 231,890
Total Assets = 390,618

Assets

Total Assets390,618
Total Current Assets318,193
Long-term Assets72,425
Total Current Assets
Cash And Cash Equivalents 86,707
Net Receivables 50,140
Inventory 171,801
Other Current Assets 9,545
Total Current Assets  (as reported)318,193
Total Current Assets  (calculated)318,193
+/-0
Long-term Assets
Property Plant Equipment 53,694
Goodwill 3,530
Intangible Assets 485
Long-term Assets Other 14,716
Long-term Assets  (as reported)72,425
Long-term Assets  (calculated)72,425
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities44,891
Long-term Liabilities113,837
Total Stockholder Equity231,890
Total Current Liabilities
Short-term Debt 1,193
Accounts payable 16,020
Other Current Liabilities 27,535
Total Current Liabilities  (as reported)44,891
Total Current Liabilities  (calculated)44,748
+/- 143
Long-term Liabilities
Long term Debt 101,326
Capital Lease Obligations 10,058
Long-term Liabilities Other 2,063
Long-term Liabilities  (as reported)113,837
Long-term Liabilities  (calculated)113,447
+/- 390
Total Stockholder Equity
Common Stock24
Retained Earnings -420,479
Other Stockholders Equity 652,345
Total Stockholder Equity (as reported)231,890
Total Stockholder Equity (calculated)231,890
+/-0
Other
Capital Stock24
Cash and Short Term Investments 86,707
Common Stock Shares Outstanding 244,804
Current Deferred Revenue143
Liabilities and Stockholders Equity 390,618
Net Debt 24,677
Net Invested Capital 333,216
Net Working Capital 273,302
Property Plant and Equipment Gross 95,042
Short Long Term Debt Total 111,384



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-30
> Total Assets 
11,253
9,033
16,663
14,652
7,805
8,787
6,569
2,647
2,647
8,028
10,108
8,688
9,270
6,844
2,934
12
3,619
3
16
9
6
8
17,008
15,884
13,225
15,555
13,817
10,690
8,702
31,980
31,951
27,883
25,287
27,227
33,928
29,800
27,824
23,715
19,685
31,742
27,495
23,685
17,595
84,639
72,813
108,019
91,138
117,752
106,345
88,877
78,120
143,274
137,780
127,091
210,524
191,542
189,976
207,673
235,667
232,814
238,640
276,253
308,032
296,932
300,558
348,462
340,788
343,027
348,997
329,182
350,875
376,399
390,618
390,618376,399350,875329,182348,997343,027340,788348,462300,558296,932308,032276,253238,640232,814235,667207,673189,976191,542210,524127,091137,780143,27478,12088,877106,345117,75291,138108,01972,81384,63917,59523,68527,49531,74219,68523,71527,82429,80033,92827,22725,28727,88331,95131,9808,70210,69013,81715,55513,22515,88417,0088691633,619122,9346,8449,2708,68810,1088,0282,6472,6476,5698,7877,80514,65216,6639,03311,253
   > Total Current Assets 
11,253
9,033
16,663
14,652
7,805
8,787
6,569
2,647
2,647
8,028
10,108
8,688
9,270
6,844
2,934
12
3,619
3
16
9
6
8
15,844
14,619
11,982
13,948
12,306
9,173
7,144
31,052
30,788
26,494
22,572
24,088
30,982
27,127
25,240
21,290
17,358
29,494
25,360
21,657
15,683
44,271
31,444
63,167
46,419
73,630
62,503
44,530
38,334
103,889
97,323
85,820
165,488
142,990
139,549
153,741
177,277
171,355
174,785
208,729
239,800
222,774
224,095
270,402
264,086
266,243
273,699
257,013
276,419
303,691
318,193
318,193303,691276,419257,013273,699266,243264,086270,402224,095222,774239,800208,729174,785171,355177,277153,741139,549142,990165,48885,82097,323103,88938,33444,53062,50373,63046,41963,16731,44444,27115,68321,65725,36029,49417,35821,29025,24027,12730,98224,08822,57226,49430,78831,0527,1449,17312,30613,94811,98214,61915,8448691633,619122,9346,8449,2708,68810,1088,0282,6472,6476,5698,7877,80514,65216,6639,03311,253
       Cash And Cash Equivalents 
11,253
9,033
16,663
14,652
7,805
8,787
6,569
2,647
2,647
8,028
10,108
8,688
9,270
6,844
2,934
12
3,619
3
16
9
6
8
14,240
12,888
10,720
12,536
10,321
7,653
5,380
26,149
26,518
17,869
13,952
17,199
16,564
7,822
9,178
10,441
8,925
12,549
7,906
9,915
8,543
25,574
13,601
43,108
26,120
55,154
42,367
22,755
16,534
73,616
48,006
26,752
101,236
75,781
59,675
55,921
61,966
42,409
34,411
51,089
69,505
52,415
34,906
86,522
69,204
62,513
74,157
51,352
45,325
88,244
86,707
86,70788,24445,32551,35274,15762,51369,20486,52234,90652,41569,50551,08934,41142,40961,96655,92159,67575,781101,23626,75248,00673,61616,53422,75542,36755,15426,12043,10813,60125,5748,5439,9157,90612,5498,92510,4419,1787,82216,56417,19913,95217,86926,51826,1495,3807,65310,32112,53610,72012,88814,2408691633,619122,9346,8449,2708,68810,1088,0282,6472,6476,5698,7877,80514,65216,6639,03311,253
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,935
2,203
6,314
6,320
4,653
11,512
15,930
11,764
6,368
2,695
11,271
11,027
5,390
245
0
0
1,500
1,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000001,5001,500002455,39011,02711,2712,6956,36811,76415,93011,5124,6536,3206,3142,2032,93500000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
220
62
39
326
237
335
0
484
804
562
384
351
522
1,201
924
944
827
1,328
1,018
840
2,292
1,500
3,880
3,658
3,797
4,127
1,392
1,310
5,087
7,315
3,470
7,108
6,514
6,335
13,237
15,362
23,545
20,393
28,577
25,630
18,884
20,902
15,505
26,518
36,732
31,319
27,421
49,621
30,113
50,140
50,14030,11349,62127,42131,31936,73226,51815,50520,90218,88425,63028,57720,39323,54515,36213,2376,3356,5147,1083,4707,3155,0871,3101,3924,1273,7973,6583,8801,5002,2928401,0181,3288279449241,2015223513845628044840335237326396222000000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
428
308
190
108
651
367
223
299
598
395
286
144
613
399
267
111
745
638
482
314
747
2,408
2,079
2,051
2,703
2,431
2,131
1,766
2,050
1,597
1,716
2,534
4,855
4,693
3,786
3,046
5,803
5,702
5,859
4,339
5,519
5,400
5,372
5,095
4,379
5,219
5,107
5,334
3,741
5,524
9,545
9,5455,5243,7415,3345,1075,2194,3795,0955,3725,4005,5194,3395,8595,7025,8033,0463,7864,6934,8552,5341,7161,5972,0501,7662,1312,4312,7032,0512,0792,4087473144826387451112673996131442863955982992233676511081903084280000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,165
1,265
1,243
1,607
1,512
1,518
1,558
927
1,164
1,389
2,716
3,139
2,946
2,673
2,584
2,424
2,327
2,248
2,136
2,028
1,912
40,368
41,369
44,852
44,718
44,122
43,842
44,347
39,786
39,385
40,456
41,270
45,036
48,552
50,428
53,933
58,390
61,459
63,855
67,523
68,232
74,158
76,463
78,060
76,701
76,784
75,298
72,169
74,456
72,708
72,425
72,42572,70874,45672,16975,29876,78476,70178,06076,46374,15868,23267,52363,85561,45958,39053,93350,42848,55245,03641,27040,45639,38539,78644,34743,84244,12244,71844,85241,36940,3681,9122,0282,1362,2482,3272,4242,5842,6732,9463,1392,7161,3891,1649271,5581,5181,5121,6071,2431,2651,1650000000000000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
815
825
804
779
802
850
811
765
829
1,039
2,381
2,841
2,738
2,628
2,519
2,397
2,296
2,221
2,109
2,001
1,882
28,627
29,756
30,467
30,616
30,337
30,363
30,116
29,695
29,444
30,713
31,741
35,061
37,373
42,405
45,852
50,373
53,316
55,085
58,198
60,327
65,502
67,282
68,747
67,618
66,309
64,568
63,470
64,714
63,478
53,694
53,69463,47864,71463,47064,56866,30967,61868,74767,28265,50260,32758,19855,08553,31650,37345,85242,40537,37335,06131,74130,71329,44429,69530,11630,36330,33730,61630,46729,75628,6271,8822,0012,1092,2212,2962,3972,5192,6282,7382,8412,3811,0398297658118508027798048258150000000000000000000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5300000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,011
5,737
4,849
4,638
4,427
4,216
4,004
3,793
3,582
3,371
3,159
2,981
2,802
2,623
2,444
2,265
2,086
1,908
1,729
1,550
1,371
1,192
1,013
835
656
477
499
321
479
485
4854793214994776568351,0131,1921,3711,5501,7291,9082,0862,2652,4442,6232,8022,9813,1593,3713,5823,7934,0044,2164,4274,6384,8495,7376,0110000000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
349
440
439
828
709
668
747
163
335
350
334
298
208
45
65
28
31
27
27
27
30
11,742
11,614
14,385
5,935
5,829
5,735
6,697
2,768
2,829
2,843
2,840
3,465
4,847
4,653
6,366
2,223
2,527
3,334
4,067
2,826
3,756
4,459
4,770
0
6,289
0
0
0
0
0
000006,28904,7704,4593,7562,8264,0673,3342,5272,2236,3664,6534,8473,4652,8402,8432,8292,7686,6975,7355,8295,93514,38511,61411,74230272727312865452082983343503351637476687098284394403490000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
245
203
282
150
308
323
307
272
181
18
38
0
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000040381818127230732330815028220324500000000000000000000000000
> Total Liabilities 
11,253
9,033
16,663
14,652
7,805
8,787
6,569
2,647
2,647
8,028
10,108
8,688
9,270
6,844
2,934
12
3,619
5
6
10
10
5
1,258
1,228
1,618
6,132
7,417
8,962
9,438
10,407
16,048
15,580
16,042
21,219
20,497
20,280
22,910
22,894
23,054
27,826
27,648
28,142
28,353
56,957
59,821
67,686
68,112
65,993
69,139
69,106
68,081
96,368
101,662
100,898
114,188
114,662
118,600
119,424
123,163
121,220
135,860
135,080
181,099
182,532
200,173
196,488
195,133
196,265
197,559
193,976
197,169
188,130
158,728
158,728188,130197,169193,976197,559196,265195,133196,488200,173182,532181,099135,080135,860121,220123,163119,424118,600114,662114,188100,898101,66296,36868,08169,10669,13965,99368,11267,68659,82156,95728,35328,14227,64827,82623,05422,89422,91020,28020,49721,21916,04215,58016,04810,4079,4388,9627,4176,1321,6181,2281,25851010653,619122,9346,8449,2708,68810,1088,0282,6472,6476,5698,7877,80514,65216,6639,03311,253
   > Total Current Liabilities 
3,616
3,866
3,572
10,072
8,508
8,409
11,058
15,958
15,958
7,458
6,858
11,508
9,908
5,808
6,708
12
8,608
5
6
10
10
5
1,027
1,006
1,404
1,817
2,101
2,029
2,517
3,658
4,303
3,797
4,119
4,198
3,787
3,200
4,298
4,217
4,291
5,083
9,208
11,223
12,958
15,645
13,339
9,440
9,443
6,917
9,893
9,625
8,338
10,129
15,150
14,028
13,908
12,880
16,474
19,947
21,206
18,186
32,337
30,378
31,567
28,072
44,440
39,267
36,728
41,952
41,841
49,806
53,088
44,177
44,891
44,89144,17753,08849,80641,84141,95236,72839,26744,44028,07231,56730,37832,33718,18621,20619,94716,47412,88013,90814,02815,15010,1298,3389,6259,8936,9179,4439,44013,33915,64512,95811,2239,2085,0834,2914,2174,2983,2003,7874,1984,1193,7974,3033,6582,5172,0292,1011,8171,4041,0061,02751010658,608126,7085,8089,90811,5086,8587,45815,95815,95811,0588,4098,50810,0723,5723,8663,616
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
10
10
12
12
12
12
13
13
13
14
14
14
14
15
15
15
16
4,461
6,128
6,684
6,667
3,860
3,318
40,467
29
29
30
210
223
230
229
194
211
276
366
318
386
501
591
654
580
721
905
956
980
983
1,045
2,186
2,284
1,193
1,1932,2842,1861,04598398095690572158065459150138631836627621119422923022321030292940,4673,3183,8606,6676,6846,1284,4611615151514141414131313121212121010100000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
0
0
0
15
0
0
0
6,111
17,544
30,855
29,369
40,211
40,467
40,899
0
0
210
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000002100040,89940,46740,21129,36930,85517,5446,1110001500014000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
5
509
791
891
1,059
1,379
1,159
1,483
2,709
2,764
2,340
2,445
1,779
1,779
1,648
2,185
2,088
2,468
3,317
2,777
2,565
3,904
4,672
9,156
5,921
5,718
3,101
5,268
5,900
5,480
6,788
8,960
9,175
9,152
6,910
7,980
11,074
12,153
6,167
17,283
12,429
14,115
11,388
25,198
13,229
12,956
12,085
10,851
15,660
17,186
14,179
16,020
16,02014,17917,18615,66010,85112,08512,95613,22925,19811,38814,11512,42917,2836,16712,15311,0747,9806,9109,1529,1758,9606,7885,4805,9005,2683,1015,7185,9219,1564,6723,9042,5652,7773,3172,4682,0882,1851,6481,7791,7792,4452,3402,7642,7091,4831,1591,3791,05989179150951000000000000000000000
       Other Current Liabilities 
3,616
3,866
3,572
10,072
8,508
8,409
11,058
15,958
0
7,458
6,858
11,508
9,908
5,808
6,708
12
8,608
5
6
10
10
5
508
205
503
747
710
789
947
860
1,451
1,368
1,585
2,329
1,918
1,463
1,949
1,968
1,662
1,605
1,825
2,385
2,225
4,161
177
58
3,582
3,644
4,453
3,552
2,506
2,974
4,763
4,481
4,419
5,617
8,075
8,365
8,592
11,490
14,410
17,215
16,655
15,961
18,379
24,989
22,672
28,746
29,864
32,919
32,598
23,750
27,535
27,53523,75032,59832,91929,86428,74622,67224,98918,37915,96116,65517,21514,41011,4908,5928,3658,0755,6174,4194,4814,7632,9742,5063,5524,4533,6443,582581774,1612,2252,3851,8251,6051,6621,9681,9491,4631,9182,3291,5851,3681,45186094778971074750320550851010658,608126,7085,8089,90811,5086,8587,458015,95811,0588,4098,50810,0723,5723,8663,616
   > Long-term Liabilities 
3,616
3,866
3,572
10,072
8,508
8,409
11,058
15,958
15,958
7,458
6,858
11,508
9,908
5,808
6,708
0
8,608
0
0
0
0
0
231
222
214
4,314
5,316
6,933
6,921
6,749
11,744
11,784
11,924
17,021
16,710
17,080
18,612
18,677
18,763
22,743
18,440
16,919
15,395
41,312
46,482
58,246
58,669
59,076
59,246
59,481
59,743
86,240
86,512
86,870
100,280
101,782
102,127
99,477
101,957
103,034
103,523
104,702
149,533
154,460
155,733
157,221
158,405
154,312
155,718
144,170
144,081
143,953
113,837
113,837143,953144,081144,170155,718154,312158,405157,221155,733154,460149,533104,702103,523103,034101,95799,477102,127101,782100,28086,87086,51286,24059,74359,48159,24659,07658,66958,24646,48241,31215,39516,91918,44022,74318,76318,67718,61217,08016,71017,02111,92411,78411,7446,7496,9216,9335,3164,314214222231000008,60806,7085,8089,90811,5086,8587,45815,95815,95811,0588,4098,50810,0723,5723,8663,616
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
87
84
81
3,851
4,869
4,888
4,909
4,930
9,736
9,765
9,915
14,824
14,940
14,037
14,156
14,283
14,413
18,078
13,818
12,341
10,861
11,151
16,324
28,128
28,377
28,772
29,040
29,320
42,347
83,774
84,095
69,594
97,961
99,511
99,904
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000099,90499,51197,96169,59484,09583,77442,34729,32029,04028,77228,37728,12816,32411,15110,86112,34113,81818,07814,41314,28314,15614,03714,94014,8249,9159,7659,7364,9304,9094,8884,8693,8518184870000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
245
203
282
150
308
323
307
272
181
18
38
0
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000040381818127230732330815028220324500000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
144
138
133
356
313
1,911
1,878
1,686
1,875
1,886
1,876
2,064
1,637
1,610
3,024
2,962
2,918
2,875
2,832
2,787
2,744
2,712
2,701
15,275
18,203
18,206
18,100
18,047
2,514
2,465
2,417
2,368
2,319
2,271
2,222
2,173,584
2,125
2,083
2,244
2,373
3,826
3,778
3,731
3,683
0
3,778
0
0
0
0
0
000003,77803,6833,7313,7783,8262,3732,2442,0832,1252,173,5842,2222,2712,3192,3682,4172,4652,51418,04718,10018,20618,20315,2752,7012,7122,7442,7872,8322,8752,9182,9623,0241,6101,6372,0641,8761,8861,8751,6861,8781,9113133561331381440000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
144
139
133
128
315
1,913
1,879
1,686
1,876
1,886
1,876
2,065
1,638
1,611
3,023
2,962
2,918
2,875
2,831
2,788
2,745
2,619
2,583
2,547
2,511
2,476
2,440
2,404
2,369
2,333
2,297
2,262
2,226
2,190
2,154
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000002,1542,1902,2262,2622,2972,3332,3692,4042,4402,4762,5112,5472,5832,6192,7452,7882,8312,8752,9182,9623,0231,6111,6382,0651,8761,8861,8761,6861,8791,9133151281331391440000000000000000000000
> Total Stockholder Equity
7,637
5,167
13,091
4,580
-703
378
-4,489
-13,311
0
570
3,250
-2,820
-638
1,036
-3,774
0
-4,989
-2
10
-1
-4
3
15,750
14,656
11,607
9,424
6,401
1,728
-736
21,573
15,904
12,303
9,245
6,009
13,430
9,520
4,914
821
-3,369
3,916
-152
-4,457
-10,758
27,682
12,993
40,333
23,025
51,759
37,206
19,770
10,039
46,906
36,118
26,193
96,336
76,879
71,376
88,249
112,504
111,594
102,780
141,173
126,933
114,401
100,385
151,974
145,655
146,762
151,437
135,206
153,706
188,269
231,890
231,890188,269153,706135,206151,437146,762145,655151,974100,385114,401126,933141,173102,780111,594112,50488,24971,37676,87996,33626,19336,11846,90610,03919,77037,20651,75923,02540,33312,99327,682-10,758-4,457-1523,916-3,3698214,9149,52013,4306,0099,24512,30315,90421,573-7361,7286,4019,42411,60714,65615,7503-4-110-2-4,9890-3,7741,036-638-2,8203,2505700-13,311-4,489378-7034,58013,0915,1677,637
   Common Stock
0
0
0
0
0
0
0
250
0
250
250
250
250
250
250
0
250
0
0
0
0
0
5
5
0
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
3
3
5
5
5
5
5
5
6
6
6
9
9
9
10
12
13
14
20
20
20
20
22
22
22
23
23
23
23
24
242323232322222220202020141312109996665555553311111111111111111005500000250025025025025025025002500000000
   Retained Earnings -420,479-456,388-488,450-506,256-488,611-491,176-484,805-478,017-465,785-450,885-437,121-412,113-395,463-377,750-358,845-340,465-321,057-304,140-283,962-264,717-254,156-242,717-229,505-216,437-198,399-183,264-168,516-150,694-137,711-122,508-113,472-106,935-102,376-98,044-92,032-87,420-82,837-77,735-73,055-69,450-65,886-62,502-58,540-52,637-47,935-45,246-40,351-37,109-34,858-31,612-30,405-154-145-140-128-123-118-1140000000000000-38-33
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
141
156
46,151
46,263
46,464
46,533
46,751
46,974
47,199
74,209
74,443
74,803
75,130
75,457
86,485
87,253
87,750
88,240
88,662
101,959
102,222
102,476
102,712
150,188
150,701
191,022
191,537
235,018
235,601
236,203
239,540
289,617
290,268
290,904
380,289
381,011
392,424
428,704
471,337
489,331
498,230
553,266
564,034
565,266
566,150
629,969
630,438
637,916
0
0
0
0
0
00000637,916630,438629,969566,150565,266564,034553,266498,230489,331471,337428,704392,424381,011380,289290,904290,268289,617239,540236,203235,601235,018191,537191,022150,701150,188102,712102,476102,222101,95988,66288,24087,75087,25386,48575,45775,13074,80374,44374,20947,19946,97446,75146,53346,46446,26346,15115614100000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
7,670
5,205
13,091
4,580
-703
378
-4,489
-13,561
0
320
3,000
-3,070
-888
786
-4,024
113
-5,121
122
139
139
141
156
46,151
46,263
46,464
46,533
46,751
46,974
47,199
75,245
74,443
74,803
75,130
76,741
86,485
87,253
87,750
89,993
88,662
101,959
102,222
104,700
102,712
150,547
151,520
192,308
193,340
237,356
238,481
239,624
243,619
294,288
295,539
296,629
380,289
381,011
392,424
428,704
471,337
489,331
498,230
553,266
564,034
565,266
566,150
629,969
630,438
637,916
640,026
641,439
642,133
644,634
652,345
652,345644,634642,133641,439640,026637,916630,438629,969566,150565,266564,034553,266498,230489,331471,337428,704392,424381,011380,289296,629295,539294,288243,619239,624238,481237,356193,340192,308151,520150,547102,712104,700102,222101,95988,66289,99387,75087,25386,48576,74175,13074,80374,44375,24547,19946,97446,75146,53346,46446,26346,151156141139139122-5,121113-4,024786-888-3,0703,0003200-13,561-4,489378-7034,58013,0915,2057,670



5.3. Balance Sheets

Currency in USD. All numbers in thousands.